The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Venus Remedies now has 29 active product approvals in Vietnam alone
Poviztra is a second brand of Wegovy
The said inspection concluded with Zero Form 483 observation
Poly Medicure has reported total income of Rs. 477.82 crore during the period ended September 30, 2025
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Subscribe To Our Newsletter & Stay Updated
